Recent News

AACR 2019: Savolitinib Plus Osimertinib in EGFR -Mutant, MET-Amplified NSCLC

ELCC 2019: Pembrolizumab Monotherapy in Elderly Patients With Advanced NSCLC

HOPA 2019: Flat-Dose Nivolumab Dosing in First-Line Treatment of NSCLC

FDA Expands Pembrolizumab Indication in First-Line Treatment of NSCLC

Novel Approach to Predicting Adverse and Beneficial Effects of Immunologic Interventions

Role for Oxoglutarate Carrier in Formation of Lung Cancer

Less Frequent Dosing of Nivolumab in NSCLC

STS 2019: Identifying Candidates for Adjuvant Therapy for Early-Stage Lung Adenocarcinoma

STS 2019: Can Mutations Predict Survival After Pulmonary Metastasectomy for Colorectal Cancer?

Thoracic Cancers Symposium 2019: Evidence-Based Decision-Making in NSCLC

ASCO-SITC 2019: Predicting Response to Immunotherapy in NSCLC

Thoracic Cancers Symposium 2019: Local Consolidative Therapy for Oligometastatic NSCLC

AACR 2019: Clinical Utility of Cell-Free DNA Liquid Biopsy in Metastatic Lung Cancer

2019 ASCO-SITC Symposium: Neoadjuvant Atezolizumab in NSCLC

2019 ESMO TAT: Predicting Outcomes With Lung Immune Prognostic Index

2019 ASCO-SITC Symposium: Vaccine Plus Nivolumab in Lung Cancer

FDA Grants Priority Review for Entrectinib in ROS1-Positive NSCLC

Optimal Timing of Surgical Resection for NSCLC

2019 STS: Novel Predictive Tool for Prolonged Air Leak After Lung Cancer Surgery

2019 STS: Imaging Nanoagent for Sentinel Lymph Node Mapping in Lung Surgery

2019 STS: How Socioeconomic Status Impacts Outcomes in Non–Small Cell Lung Cancer

2019 STS: Impact of Regionalization of Lung Cancer Surgery on Outcomes

2019 STS: Stage Correlation, Guideline-Concordant Care, and Survival in NSCLC

FDA Accepts sBLA for Atezolizumab Plus Chemotherapy in First-Line Treatment of Metastatic NSCLC

2019 STS: Opioid Use Varies Among Elderly After Lung Resection

FDA Expands Pemetrexed Indication With Pembrolizumab and Chemotherapy in First-Line Treatment of NSCLC

2019 STS: Can Patients Over Age 90 Benefit From NSCLC Treatment?

Academic vs. Community-Based Centers: Survival Disparities Among Patients With NSCLC?

KEYNOTE-010 in Advanced NSCLC: Long-Term Survival Benefit With Pembrolizumab

How Accurate Are NCDB Comorbidity Assessments in Lung Cancer and Other Resected Tumors?

OAK Trial: Disease Progression With Atezolizumab vs Chemotherapy in NSCLC

First-Line Immunotherapy Combination in Lung Cancer

Early Research of Birabresib in Lung Cancer and Other Solid Tumors

Is More Frequent Surveillance Associated With Better Survival for Patients With NSCLC?

FDA Approves Atezolizumab Combination in First-Line Treatment of Metastatic Nonsqumous NSCLC

Radiation-Based Trimodality Therapy in Stage III NSCLC

Combined Immunotherapy Treatment Studied in Advanced Lung Cancer

Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors

FDA Approves Larotrectinib in Solid Tumors With NTRK Gene Fusion

Palliative and Supportive Care Symposium: Immunotherapy-Related Toxicities

ESMO 2018: Neoadjuvant Erlotinib in Stage IIIA-N2 Lung Cancer

ESMO 2018: Single-Agent Nazartinib in EGFR-Mutant Lung Cancer

ASTRO 2018: Nelfinavir in Stage III Locally Advanced Lung Cancer

ESMO 2018: Resistance Mechanisms in Patients Treated with Osimertinib for Lung Cancer

ESMO 2018: Uncommon EGFR Mutations in Lung Adenocarcinoma

FDA Approves Lorlatinib in ALK-Positive Metastatic NSCLC

FDA Approves Pembrolizumab With Chemotherapy as First-Line Treatment of Metastatic NSCLC

Are Immune-Related Adverse Events Similar in Men and Women?